Continuous spike-wave during sleep ESES Electrical status epilepticus in sleep non-REM Non-rapid eye movement AIM To evaluate the efficacy of clobazam treatment in reducing epileptiform discharges and modifying neuropsychological function in continuous spike-wave during slow wave sleep.
More than 1 percent of the general pediatric and adult population, and most patients with epilepsy, [1] [2] [3] have epileptiform discharges on electroencephalogram (EEG). Research findings suggest that epileptiform discharges disrupt short-term cognitive processes in humans such as scholastic tasks in children 4 and driving tasks in adults. 5 In contrast, the impact of epileptiform discharges on longterm learning and cognition remains unclear. [6] [7] [8] There is some evidence suggesting that the underlying etiology is the main determinant of long-term cognitive outcomes of patients, with epileptiform discharges solely being biomarkers of the underlying etiology. 7 However, there is also evidence that epileptiform discharges are associated with long-term cognitive dysfunction independent from the underlying etiology. 9 Electrical status epilepticus in sleep (ESES) is one of the most extreme models illustrating the association between epileptiform discharges and cognitive impairment. 10 The most severe expression of ESES is continuous spike-wave during sleep (CSWS), a condition characterized by refractory epilepsy, ESES on the EEG, and severe cognitive regression. 10 Previous series suggest that surgical treatment of CSWS improves cognitive outcomes. [11] [12] [13] Medical treatment reduces epileptiform discharges, [14] [15] [16] but the impact on long-term cognitive effects is not clear. 17 The present prospective clinical trial aims to answer this gap in knowledge by evaluating whether reduction in epileptiform discharges in CSWS is associated with cognitive improvement.
METHOD Ethical approval and patient consent
This study was approved by the Institutional Review Board at Boston Children's Hospital. The parent or legal guardian of each participant provided informed consent. Each participant, when developmentally able to, provided assent to participate in the study.
Study design
This is a prospective clinical trial (clinicaltrials.gov identifier: NCT02127918). Patients underwent a first neuropsychological assessment shortly after the clinical suspicion of CSWS was confirmed in our institution, and before the initial overnight video-EEG monitoring in which clobazam treatment was initiated. After 3 months of treatment, a second neuropsychological assessment and a second overnight video-EEG monitoring were performed (Fig. S1 , online supporting information).
Participants
The inclusion criteria for the study were: (1) patients between 2 years and 21 years of age admitted for overnight video-EEG monitoring because of a clinical suspicion of CSWS; (2) electroclinical confirmation of CSWS; (3) addition of clobazam treatment to the baseline treatment. The exclusion criteria were: (1) no clinical need to modify medication regimen or changes in the baseline treatment that do not involve clobazam; (2) pregnancy (as confirmed by a urine test performed as part of the study before starting the medication); (3) discontinuation of clobazam treatment before the 3-month time.
The minimum duration of overnight video-EEG monitoring was 18 hours. The diagnosis of CSWS was confirmed based on neuropsychological regression in at least one domain of development, the presence of seizures that appear in an age-related manner, and the presence of the ESES pattern in the EEG. 10 
Clobazam treatment
A treatment cycle of nocturnal clobazam consisted of oral administration of 1mg/kg clobazam (maximum 30mg) before sleep on the first night followed by 0.5mg/kg before sleep each night during the following 3 months. These doses were the maximum doses allowed by the Institutional Review Board for this study.
EEG assessment
All patients underwent continuous overnight EEG monitoring to study the electrographic pattern of ESES and quantify epileptiform discharges. Scalp electrodes were placed according to the International 10-20 system. EEG recordings were continuously monitored throughout the day and night by dedicated EEG technologists. For the purposes of this study, a patient was considered to exhibit ESES in the EEG when the spike percentage during nonrapid eye movement (non-REM) sleep was 50 percent or more. As any other threshold, the 50 percent threshold is arbitrary and intended as a study inclusion criterion, not as a definition of the syndrome. The ESES EEG pattern has been traditionally described as having at least 85 percent occupied by epileptiform activity during non-REM sleep. For comparison with prior studies, we also described this threshold in the results. Spike percentage was defined as the percentage of seconds occupied by at least one epileptiform discharge. 18 Spike frequency was defined as the total number of epileptiform discharges in 100 seconds. 18 Quantification of epileptiform activity was calculated during the first 5 minutes of non-REM sleep. 18 The beginning of non-REM sleep was defined as the segment that began 1 minute after the first appearance of vertex waves. EEG data were analyzed by two clinical neurophysiologists (JP and MST-S) blinded to clinical data. In case of discrepancy by more than 10 percent in spike percentage as independently rated, EEG was reviewed and assessed by a third neurophysiologist. Data from each clinical neurophysiologist was averaged to conduct analysis. Quantification of epileptiform discharges was performed in two different time points for each patient: immediately before initiation of clobazam treatment and 3 months after initiation treatment.
Clinical assessment
Demographic and basic clinical variables included age, sex, seizure types, antiepileptic treatments, and comorbid neuropsychiatric conditions.
A battery of neuropsychological tests was performed by a board-certified clinical neuropsychologist (CV) or by a research assistant under the supervision of the neuropsychologist. The test battery included:
Differential Ability Scales-Second Edition: this is a measure of overall intelligence with indexes that measure verbal, nonverbal, and visual spatial skills. 19 Peabody Picture Vocabulary Test-Fourth Edition: this is a measure of receptive vocabulary knowledge that requires patients to point to one of four choices of pictures corresponding to the word provided by the examiner. 20 A Developmental NEuroPSYchological Assessment-Second Edition (NEPSY-2): this is a measure of verbal fluency that requires production of words within specific semantic categories (e.g. animals, things you can eat or drink) and beginning with specific letters (S and F). 21 Behavior Rating Inventory of Executive Function: this is a parent report questionnaire for patients aged 3 to 5 years, or 5 to 18 years that assesses executive functioning in the environment including behavioral regulation, and metacognitive skills such as working memory, organization, planning, and problem-solving. 22 Child Behavior Checklist: this parent report questionnaire assesses behavioral, social, and emotional functioning in the environment for patients aged 2 to 5 years, or 6 to 18 years. 23 Scales of Independent Behaviors-Revised: this parent report questionnaire measures adaptive and daily living skill including communication, motor, self-care, and community living skills in patients beginning in infancy to 80 years of age. 24 Standard scores for all tests were derived from published norms.
Statistical analyses
Demographics and clinical characteristics were summarized with descriptive statistics. The variables departed from the assumption of a normal distribution and non-parametric measures and tests were performed. Measures of What this paper adds
• Verbal IQ in patients with continuous spike-wave during sleep improved following short-term treatment with clobazam.
• Other neuropsychological improvements were observed, but varied by patient.
• Cognitive improvement was observed despite some worsening of epileptiform discharges.
epileptiform discharges and neuropsychological function before and after clobazam treatment were compared qualitatively because of the small sample size. CSWS is a rare condition, therefore the size of our study population was mainly determined by the availability of patients. Further, data on the efficacy of different treatments for CSWS is limited, therefore a quantitative calculation of sample size would have relied on data with too wide confidence intervals and was not feasible. All analyses were performed with R (version 3.2.2): a language and environment for statistical computing (R core team, 2015; R foundation for Statistical Computing, Vienna, Austria. www.R-project.org/).
RESULTS
Seventeen patients initiated clobazam treatment of whom five discontinued the treatment early (two because of side effects -agitation in one patient and agitation/irritability in another; two because of loss for follow-up; and one because of epilepsy surgery in the interim). Among the remaining 12 patients, neuropsychological assessment was not possible in every patient because of severe behavioral dysregulation or a significant degree of cognitive impairment that did not allow patients to complete standardized testing beyond basic requirements. Details of reasons for exclusion are described in Table SI , online supporting information. Pre-and post-treatment measures were available for nine patients who constituted our study population (Table I ). For comparison with the studied population, we briefly report on the characteristics of the excluded patients (Table SI) . The classical threshold for ESES requires at least 85 percent of non-REM sleep occupied by epileptiform activity. Following this arbitrary threshold, none of our patients met that threshold pre-clobazam treatment and patient 9 met that threshold after clobazam treatment. (Table II and Fig. 2) . Clinically significant difficulties with various aspects of executive functioning were endorsed by parents including poor behavioral regulation (e.g. inhibition, shifting, and emotional control) as well as decreased metacognitive skills (initiation, working memory, planning, organization, and self-monitoring) before treatment. At baseline, the group also exhibited clinically significant social difficulties, as well as problems with behavior such as conduct, aggression, oppositionality, and attentiondeficit-hyperactivity disorder symptoms. A decrease in affective problems (i.e. anxiety and depression symptoms) and behavioral problems specifically associated with oppositional behavior was noted after treatment. No evidence of improvement in executive functions or adaptive/self-care skills in the environment was observed (Table SIII, online supporting information).
Epileptiform discharges response to clobazam treatment
Three patients (3, 4, and 6; 33%) were considered 'strong responders,' demonstrating a decrease in epileptiform activity greater than 50 percent compared to the original value. One of the strong responders experienced clinical seizures in addition to CSWS before beginning the study, and all were seizure free after the introduction of clobazam for the duration of the trial. Two additional patients (2 and 5) also showed a decrease in epileptiform activity and were considered moderate responders as they had a decrease in epileptiform activity of less than 50 percent compared to the original value, and neither experienced clinical seizures at treatment onset or for the duration of the trial. Non-responders were those who had an increase in epileptiform activity after clobazam treatment. To measure individual neuropsychological change in the five patients who showed a positive improvement on EEG resulting from clobazam treatment, reliable change indices correcting for practice effects were calculated for those tests with available test-retest reliability data. For parent questionnaires, change was defined as a difference of one standard deviation. Reliable change indices analysis showed one patient improving in Verbal IQ (2) and another improving in Non-verbal IQ (6), two improving in spatial IQ (5 and 6), and two improving on receptive language (4 and 5). In addition to improvement on cognitive tests, patient 6 showed decreased attention problems and aggression, and improved executive functioning. In contrast, although patient 2 performed better on Verbal IQ, increased difficulties with spatial IQ, verbal fluency, attention, and executive functioning were evident after treatment. One patient (7) who responded to treatment showed improved social skills (7) after treatment. However, we did not find a consistent pattern of neuropsychological improvement for every patient that responded well to treatment based on EEG improvement. For example, patient 6 continued to show average range IQ values after treatment, which remained unchanged from baseline testing. In contrast, patient 2 responded to treatment (although not considered a significant responder) yet exhibited worse neuropsychological functioning at 3-month follow up; of note, premorbid clinical presentation included a history of early language and motor delays, and lower cognitive skills before treatment initiation.
DISCUSSION

General findings
Our results demonstrate an improvement in Verbal IQ in some patients treated with clobazam for 3 months, even in patients with limited decrease in epileptiform discharges. There were no changes in general IQ or in Non-verbal IQ. Epileptiform discharges appear in virtually all patients with epilepsy and are considered a marker of epileptogenicity. The deleterious effect of epileptiform discharges on short-term cognitive processes is well established and relates to the topographical area where epileptiform discharges occur. 8 When epileptiform discharges are particularly frequent, the question arises of whether they are a biomarker of the underlying epilepsy with no specific cognitive effect, 7 or whether they independently contribute to worse long-term cognitive outcomes. 6 In a series of 103 children with medically refractory focal epilepsy, epileptiform discharges were independently associated with worse long-term cognitive outcomes. 9 Further, epileptiform discharges lateralized to the left hemisphere affected language in excess of the influence of left-sided brain pathology. 9 Patients with CSWS who undergo surgical resection of an abnormal seizure focus show improvements in cognitive function after surgery. [11] [12] [13] In a series of patients with CSWS treated with epilepsy surgery and evaluated with neuropsychological tests preand postsurgery, improvement of cognitive function occurred in three out of five patients. 12 In a series of 13 patients in which CSWS was secondary to early developmental brain lesions, surgery (anterior corpus callosotomy in six patients, total corpus callosotomy in three, hemispherectomy in two, and lobar resection in two) halted cognitive deterioration in all but one patient, and improved cognition up to 10 IQ points in three patients. 13 These improvements can be attributed to either reduction of epileptiform discharges, seizure control, or elimination of the underlying etiology. A recent series of 11 patients with CSWS treated with hemispherotomy compared their performance after surgery with the performance of a matched control group with lesional epilepsy: both groups had their primary lesion resected and both groups improved seizure control but only the patients with CSWS had language improvement. 11 These results suggest that epileptiform discharges independently contribute to long-term cognitive outcomes and that they can respond to treatment.
Only a small proportion of patients with epilepsy benefit from epilepsy surgery. Whether medical treatment to treat epileptiform discharges improves long-term cognitive outcomes is a matter of intense debate. [6] [7] [8] Treatment with high-dose diazepam decreases epileptiform discharges in both the short-and long-term. 15, 16 A double-blind crossover study on the effect of levetiracetam on patients with ESES showed improvement of epileptiform discharges to treatment, 14 but results on cognition were inconclusive. 17 The present study adds to prior literature because it demonstrates that even small reductions in epileptiform discharges improve language in a relatively short period in a segment of this often significantly disabled population. Our study is concordant with prior studies showing an improvement of epileptiform discharges to treatment [14] [15] [16] and is also concordant in that it shows a benefit in cognitive performance in the language domain. 9, 11 Our study adds to prior literature by demonstrating that a relatively short treatment course can improve cognitive performance.
In a large series of 61 patients with well-controlled or mild epilepsy, lamotrigine reduced epileptiform activity and improved behavior. 25 In a series of 10 children with incompletely controlled epilepsy, treatment with valproate (nine patients) or clobazam (one patient) reduced epileptiform activity in all patients and improved psychosocial function in eight patients. 26 Levetiracetam also appears to decrease epileptiform activity. 
Strengths and weaknesses
The main limitation of our study is the small sample size. The changes in many of the relevant outcome measures are quantitatively large and the limited ability to analyze differences with statistical tests can be related to limited power and loss to follow-up. Further, the small sample size does not allow subgroup analyses. In our series, some patients showed a clearer response than others, but the small sample size does not allow us to identify the factors that may have led to response, or lack thereof, or statistically analyze their different response to treatment. Patients 1, 7, 8, and 9 had an increase in epileptiform activity after clobazam treatment. In contrast, all of them had some improvement in IQ. Even if clobazam contributes to an increase in epileptiform activity, its overall effect on intellectual performance was positive in a portion of the study population. Natural variability in epileptiform activity from night to night may also account for these differences and future studies may benefit from a more stable quantification using the average quantification of several nights.
The Verbal IQ improved in all patients after clobazam treatment except for patient 4 in whom the Verbal IQ remained unchanged after clobazam treatment. Curiously, the largest improvement in Verbal IQ occurred in patient 9, who had worsening of epileptiform activity. This may reflect the fact that the initial neuropsychological evaluation was limited for this patient and prorated using five subtests (Table II) . However, it can also reflect an outlier in our limited sample size, or that epileptiform activity is not related to Verbal IQ. Consistent with previous studies that prospectively investigate CSWS treatment, patient numbers are relatively small. In addition, the efficacy of clobazam is limited to short-term analysis (i.e. 3mo), therefore the sustainability and ecological significance of this treatment response remains to be shown.
The use of a spike percentage threshold of 50 percent as inclusion criterion for ESES, as the use of any other threshold, is arbitrary. 27 We intended the 50 percent threshold to represent an inclusion criterion for the present study and not as a definition. There is no literature that compares the various thresholds to currently support one criterion as more appropriate.
The doses used for this study were the maximum doses allowed by the Institutional Review Board. Despite these doses being submaximal there was a measurable benefit in terms of epileptiform activity or cognitive function in most patients. In our study, other medications were not changed during the study period and therefore it evaluates the effect of clobazam on outcomes without the impact of changes in other medications. Another strength of our study is that it measures cognitive function objectively before and after treatment.
CONCLUSION
Our results demonstrate an improvement in Verbal IQ in patients treated with clobazam for 3 months. There were no changes in Global IQ or in Non-verbal IQ.
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Figure SI: Summary of the treatment protocol. 
